Propylene glycol mono-t-butyl ether (PGMBE) is a widely used solvent in industry and in consumer products, posing a potential for human exposure via inhalation or dermal routes. Toxicokinetic studies were conducted on F344/N rats and B6C3F1 mice of both sexes to evaluate single or repeated dose, species, and/or sex differences in PGMBE elimination kinetics following intravenous or inhalation exposure. In the first study, rats and mice received a single intravenous dose of 15 or 200 mg PGMBE/kg and serial blood samples were collected and analyzed for PGMBE. In the second study, rats and mice received a single 6-h whole-body inhalation exposure to 75, 300, or 1200 ppm PGMBE and serial blood samples were collected and analyzed for PGMBE. In the third study, rats and mice received whole-body inhalation exposures to 75, 300, or 1200 ppm PGMBE for 6 h/day, 5 days/wk for 14 (rats) or 16 (mice) wk. Serial blood samples were analyzed for PGMBE after 2, 6, 14 (rats), and 16 (mice) wk on study. Urine samples were also collected for 16 h postexposure and analyzed for creatinine and PGMBE sulfate and PGMBE glucuronide conjugates. These studies revealed that: (1) PGMBE was eliminated from blood following concentration-dependent nonlinear kinetics in both species; (2) saturable Michaelis-Menten kinetics were clearly exhibited following a single inhalation exposure at 1200 ppm, but were less obvious following repeated exposures; (3) mice were more efficient in eliminating PGMBE from blood at lower exposure concentrations (i.e., < or = 300 ppm), but at exposure concentrations potentially exceeding their elimination capacity, mice had a greater concentration-dependent decrease in PGMBE elimination than rats; (4) there were minimal but consistent sex differences in PGMBE elimination profiles for rats, with females having higher blood concentrations at all exposure concentrations and sampling times; and (5) sex differences in PGMBE elimination were in part associated with differences in urinary excretion of PGMBE metabolites.
...Propylene glycol mono-tert-butyl ether was found to be rapidly absorbed, metabolized, and excreted, largely within 24 hr via the urine, lungs (as carbon dioxide), and, to a lesser extent, the feces, after administration of a single oral dose to rats.
Section 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE Product identifiers Product name : 1-tert-Butoxy-2-propanol CAS-No. : 57018-52-7 Relevant identified uses of the substance or mixture and uses advised against Identified uses : Laboratory chemicals, Manufacture of substances Section 2. HAZARDS IDENTIFICATION Classification of the substance or mixture Classification according to Regulation (EC) No 1272/2008 [EU-GHS/CLP] Flammable liquids (Category 3) Serious eye damage (Category 1) Classification according to EU Directives 67/548/EEC or 1999/45/EC Flammable. Risk of serious damage to eyes. Label elements Labelling according Regulation (EC) No 1272/2008 [CLP] Pictogram Signal word Danger Hazard statement(s) H226 Flammable liquid and vapour. H318 Causes serious eye damage. Precautionary statement(s) P280 Wear protective gloves/ eye protection/ face protection. P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Supplemental Hazard none Statements According to European Directive 67/548/EEC as amended. Hazard symbol(s) R-phrase(s) R10 Flammable. R41 Risk of serious damage to eyes. S-phrase(s) S26 In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S39 Wear eye/face protection. Other hazards - none Section 3. COMPOSITION/INFORMATION ON INGREDIENTS Substances Synonyms : Propylene glycol 1-tert-butyl ether Formula : C7H16O2 Molecular Weight : 132,2 g/mol Component Concentration 1-tert-Butoxypropan-2-ol CAS-No. 57018-52-7 - EC-No. 406-180-0 Index-No. 603-129-00-6 Section 4. FIRST AID MEASURES Description of first aid measures General advice Consult a physician. Show this safety data sheet to the doctor in attendance. If inhaled If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician. In case of skin contact Wash off with soap and plenty of water. Consult a physician. In case of eye contact Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician. If swallowed Do NOT induce vomiting. Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician. Most important symptoms and effects, both acute and delayed Dizziness, Cough, Difficulty in breathing, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Indication of any immediate medical attention and special treatment needed no data available Section 5. FIREFIGHTING MEASURES Extinguishing media Suitable extinguishing media Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide. Special hazards arising from the substance or mixture Carbon oxides Advice for firefighters Wear self contained breathing apparatus for fire fighting if necessary. Further information Use water spray to cool unopened containers. Section 6. ACCIDENTAL RELEASE MEASURES Personal precautions, protective equipment and emergency procedures Use personal protective equipment. Avoid breathing vapors, mist or gas. Ensure adequate ventilation. Remove all sources of ignition. Evacuate personnel to safe areas. Beware of vapours accumulating to form explosive concentrations. Vapours can accumulate in low areas. Environmental precautions Prevent further leakage or spillage if safe to do so. Do not let product enter drains. Methods and materials for containment and cleaning up Contain spillage, and then collect with an electrically protected vacuum cleaner or by wet-brushing and place in container for disposal according to local regulations (see section 13). Reference to other sections For disposal see section 13. Section 7. HANDLING AND STORAGE Precautions for safe handling Avoid inhalation of vapour or mist. Keep away from sources of ignition - No smoking.Take measures to prevent the build up of electrostatic charge. Conditions for safe storage, including any incompatibilities Store in cool place. Keep container tightly closed in a dry and well-ventilated place. Containers which are opened must be carefully resealed and kept upright to prevent leakage. Air and moisture sensitive. Store under inert gas. Specific end use(s) no data available Section 8. EXPOSURE CONTROLS/PERSONAL PROTECTION Control parameters Components with workplace control parameters Exposure controls Appropriate engineering controls Handle in accordance with good industrial hygiene and safety practice. Wash hands before breaks and at the end of workday. Personal protective equipment Eye/face protection Tightly fitting safety goggles. Faceshield (8-inch minimum). Use equipment for eye protection tested and approved under appropriate government standards such as NIOSH (US) or EN 166(EU). Skin protection Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique (without touching glove's outer surface) to avoid skin contact with this product. Dispose of contaminated gloves after use in accordance with applicable laws and good laboratory practices. Wash and dry hands. The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and the standard EN 374 derived from it. Body Protection Complete suit protecting against chemicals, Flame retardant antistatic protective clothing, The type of protective equipment must be selected according to the concentration and amount of the dangerous substance at the specific workplace. Respiratory protection Where risk assessment shows air-purifying respirators are appropriate use a full-face respirator with multi-purpose combination (US) or type ABEK (EN 14387) respirator cartridges as a backup to engineering controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use respirators and components tested and approved under appropriate government standards such as NIOSH (US) or CEN (EU). Section 9. PHYSICAL AND CHEMICAL PROPERTIES Information on basic physical and chemical properties a) Appearance Form: clear, liquid Colour: colourless b) Odour no data available c) Odour Threshold no data available d) pH no data available e) Melting point/freezing no data available point f) Initial boiling point and 143 - 145 °C - lit. boiling range g) Flash point 44 °C - closed cup h) Evaporation rate no data available i) Flammability (solid, gas) no data available j) Upper/lower no data available flammability or explosive limits k) Vapour pressure no data available l) Vapour density no data available m) Relative density 0,874 g/cm3 at 20 °C n) Water solubility no data available o) Partition coefficient: n- no data available octanol/water p) Auto-ignition no data available temperature q) Decomposition no data available temperature r) Viscosity no data available s) Explosive properties no data available t) Oxidizing properties no data available Other safety information no data available Section 10. STABILITY AND REACTIVITY Reactivity no data available Chemical stability no data available Possibility of hazardous reactions no data available Conditions to avoid Avoid moisture. Heat, flames and sparks. Incompatible materials Strong acids, Strong oxidizing agents Hazardous decomposition products Other decomposition products - no data available Section 11. TOXICOLOGICAL INFORMATION Information on toxicological effects Acute toxicity no data available Skin corrosion/irritation no data available Serious eye damage/eye irritation no data available Respiratory or skin sensitization no data available Germ cell mutagenicity no data available Carcinogenicity IARC: 3 - Group 3: Not classifiable as to its carcinogenicity to humans (1-tert-Butoxypropan-2-ol) Reproductive toxicity no data available Specific target organ toxicity - single exposure no data available Specific target organ toxicity - repeated exposure no data available Aspiration hazard no data available Potential health effects Inhalation May be harmful if inhaled. May cause respiratory tract irritation. Ingestion May be harmful if swallowed. Skin May be harmful if absorbed through skin. May cause skin irritation. Eyes Causes eye burns. Signs and Symptoms of Exposure Dizziness, Cough, Difficulty in breathing, To the best of our knowledge, the chemical, physical, and toxicological properties have not been thoroughly investigated. Additional Information RTECS: UB3772000 Section 12. ECOLOGICAL INFORMATION Toxicity no data available Persistence and degradability no data available Bioaccumulative potential no data available Mobility in soil no data available Results of PBT and vPvB assessment no data available Other adverse effects no data available Section 13. DISPOSAL CONSIDERATIONS Waste treatment methods Product Burn in a chemical incinerator equipped with an afterburner and scrubber but exert extra care in igniting as this material is highly flammable. Offer surplus and non-recyclable solutions to a licensed disposal company. Contaminated packaging Dispose of as unused product. Section 14. TRANSPORT INFORMATION UN number ADR/RID: 1987 IMDG: 1987 IATA: 1987 UN proper shipping name ADR/RID: ALCOHOLS, N.O.S. (1-tert-Butoxypropan-2-ol) IMDG: ALCOHOLS, N.O.S. (1-tert-Butoxypropan-2-ol) IATA: Alcohols, n.o.s. (1-tert-Butoxypropan-2-ol) Transport hazard class(es) ADR/RID: 3 IMDG: 3 IATA: 3 Packaging group ADR/RID: III IMDG: III IATA: III Environmental hazards ADR/RID: no IMDG Marine Pollutant: no IATA: no Special precautions for user no data available SECTION 15 - REGULATORY INFORMATION N/A
Method for manufacturing pigment dispersed liquid, and pigment dispersed liquid, and ink for ink-jet printer recording using said pigment dispersed liquid
申请人：SEIKO EPSON CORPORATION
公开号：US20020088375A1
公开（公告）日：2002-07-11
A method for manufacturing a pigment dispersed liquid, comprising at least:
Step A of introducing a hydrophilic dispersibility-imparting group directly and/or via another atomic group to the surface of pigment particles;
Step B of dispersing the pigment obtained in Step A in an aqueous medium; and
Step C of conducting refining treatment of the dispersed liquid obtained in Step B.
AQUEOUS CURABLE COMPOSITION AND WATER-SOLUBLE PHOTOPOLYMERIZATION INITIATOR
申请人：FUJIFILM CORPORATION
公开号：US20180362558A1
公开（公告）日：2018-12-20
An aqueous curable composition includes a water-soluble photopolymerization initiator having a structure in which one or more carbonyl groups further directly bond to an aromatic ring of an aromatic acyl group that bonds to a phosphorus atom in an acylphosphine oxide structure, water, and a polymerizable compound. A novel water-soluble photopolymerization initiator is a compound represented by formula 1-1 or formula 2-1.
MOLECULAR PRECURSOR COMPOUNDS FOR ZINC-GROUP 13 MIXED OXIDE MATERIALS
申请人：Precursor Energetics, Inc.
公开号：US20150218190A1
公开（公告）日：2015-08-06
Molecular precursor compounds, processes and compositions for making Zn-Group 13 mixed oxide materials including IZO, GZO, AZO and BZO, by providing inks comprising a molecular precursor compound having the formula M
A
a
Zn(OROR)
3a+2
, and printing or depositing the inks on a substrate. The printed or deposited ink films can be treated to convert the molecular precursor compounds to a material.
Design, Synthesis, and Evaluation of Orally Active 4-(2,4-Difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-<i>f</i>][1,2,4]triazines as Dual Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Inhibitors
作者：Robert M. Borzilleri、Xiaoping Zheng、Ligang Qian、Christopher Ellis、Zhen-wei Cai、Barri S. Wautlet、Steve Mortillo、Robert Jeyaseelan,、Daniel W. Kukral、Aberra Fura、Amrita Kamath、Viral Vyas、John S. Tokarski、Joel C. Barrish、John T. Hunt、Louis J. Lombardo、Joseph Fargnoli、Rajeev S. Bhide
DOI：10.1021/jm0501275
日期：2005.6.1
A series of substituted 4-(2,4-difluoro-5-(methoxycarbamoyl)phenylamino)pyrrolo[2,1-f][1,2,4]triazines was identified as potent and selective inhibitors of the tyrosine kinase activity of the growth factor receptors VEGFR-2 (Flk-1, KDR) and FGFR-1. The enzyme kinetics associated with the VEGFR-2 inhibition of compound 50 (K(i) = 52 +/- 3 nM) confirmed that the pyrrolo[2,1-f][1,2,4]triazine analogues
NOVEL NITRILE AND AMIDOXIME COMPOUNDS AND METHODS OF PREPARATION
申请人：Lee Wai Mun
公开号：US20090111965A1
公开（公告）日：2009-04-30
The present application relates to semiconductor processing compositions comprising at least one compound containing at least one amidoxime functional group and to methods of using these compositions in semiconductor processing. The present application also describes the preparation of amidoximes for a semiconductor processing composition by (a) mixing a cyanoethylation catalyst, a nucleophile and an alpha-unsaturated nitrile to produce a cyanoethylation product; and (b) converting a cyano group in the cyanoethylation product into an amidoxime functional group.
